

OBT'S INNOVATIVE APPROACH TO NOVEL CANCER THERAPIES

THERAPIES FOR HIGH-RISK PATIENTS

OBT is developing OBT076, an innovative ADC to overcome immune suppression, for high-risk cancer patients

PATIENT CENTRIC DRUG DEVELOPMENT

OBT maintains a patient centric development approach by utilizing a tailored companion diagnostic for each development program.

DEFINITIVE TARGET DISCOVERY

OBT has established a definitive approach to tumor antigen discovery for BiTE®, ADC, CAR-T and IO through OGAP®, the largest cancer specific membrane protein library for antibody discovery and development.

NEXT GENERATION CHECKPOINT MODULATORS

OBT is developing a next generation of check modulators both as monoclonal and bispecific antibodies.

EXPERT TEAM

The company has a science and medically driven management team supported by a strong board of internationally renowned oncologists and onco-scientists.